Haematologic Technologies Announces David Sunseri, Ph.D., as President and Chief Executive Officer

March 1, 2021| Category: News

David Sunseri, Ph.D. to Lead the Company Through Next Phase of Growth

March 1, 2021 – Essex Junction, VT:  Haematologic Technologies (“HTI”), a global leader in large molecule bioanalysis and biologic reagents, today announced the appointment of David Sunseri, Ph.D. as President and Chief Executive Officer. David will lead the next phase of the Company’s growth, solidifying and expanding HTI’s position as a leading Contract Research Organization focused on large molecules and an innovator of biologic reagents and sample collection devices for the research and diagnostic markets.

David formerly served as CEO of PMI BioPharma Solutions, a specialty CDMO providing protein-based research, target validation, functional characterization, advanced assay development, and GMP manufacturing services. There he led the company through a transition from a corporate pharmaceutical ownership to a private company focused on contract services until its sale to private equity in 2020, and subsequent name change to August Bioservices.

Prior to PMI, David was Vice President of Product Development at Berg, a bio-pharmaceutical company specializing in drug discovery and related R&D utilizing artificial intelligence to identify potential drug therapies. At Berg, David was responsible for all development and GMP manufacturing operations. Prior to Berg, David led Merck’s external partner business and operational activities related to its inhalation and women’s health portfolio. Within this role, David was responsible for the identification and integration of external analytical testing laboratories into Merck’s supply chain. He started his career at Schering Plough as an analytical chemist and quickly promoted to leadership roles within technical operations. David received his BS in Chemistry from the University of North Alabama and Ph.D. in Analytical Chemistry from the Florida State University.

“HTI has built a strong reputation across the biopharmaceutical industry with its world-class technical team, a focus on science, quality, and excellence in customer service.” said David Sunseri. “I’m excited to lead this team and company, which has unique capabilities and untapped potential. HTI is deeply committed to our customers’ success and helping them bring life-changing and life-saving therapies to patients. I am excited to continue the growth of HTI by investing in expanding our capabilities and building out the team to serve our customers’ growing needs.”

“We are thrilled to have David at the helm as CEO to lead HTI through this next phase of growth,” said Brian Scanlan, Chairman of HTI’s Board. “David knows our market and our customers intimately, having spent his career at both Big Pharma and smaller, innovative contract services organizations. He understands the critical needs and expectations of our customers, the regulatory environment where we operate, and the role service organizations, like HTI, play in support of breakthrough therapeutics.”

About HTI:

Haematologic Technologies (HTI) is a leading provider of analytical services to support the research, development, and commercialization of large molecule biotherapeutics and reagents for coagulation research. HTI has deep expertise in protein biochemistry, including characterization of plasma proteins and other large molecules, and performs highly advanced assay development and GMP testing in the areas of immunoassays, thrombin generation assays, assessment of hemostatic risk, anti-drug antibody testing (immunogenicity), host cell protein mitigation, stability, and release testing, as well as a variety of other specialized assays for biotherapeutics supporting discovery through commercial release. HTI’s biopharma services are performed in fully compliant, FDA-inspected GMP facilities.

Building on its 30+ years of expertise in plasma proteins, hemostasis and blood coagulation, HTI is also a leading global supplier of coagulation research reagents (plasma proteins and antibodies), custom formulated IVD/POC device reagents, as well as customized blood collection tubes to support clinical trials. Visit us at www.haemtech.com.